Dr. Lieberman is the Chair in Cellular and Molecular Medicine at Boston Children’s Hospital and Professor, Department of Pediatrics, Harvard Medical School. In addition to being at the forefront of developing RNAi-based therapeutics and using RNAi for genome-wide screening, Dr. Lieberman led a team that discovered the molecular basis for inflammatory cell death (pyroptosis) triggered by invasive bacteria and other danger signals.
Prior to her appointments at Harvard, she was a postdoctoral fellow in immunology at MIT. Before that she earned an M.D. in the joint Harvard-MIT Program in Health, Science, and Technology and trained in internal medicine and hematology-oncology at Tufts Medical Center. Dr. Lieberman received a Ph.D. in physics from Rockefeller University and also served as a high-energy physicist at the prestigious Institute for Advanced Study in Princeton. Dr. Lieberman earned her A.B. at Radcliffe College.
She has been widely recognized by the scientific and medical communities, including being elected to the American Academy of Arts and Sciences and named Special Fellow of the Leukemia Society of America and a Pew Scholar in the Biomedical Sciences.